SEC Form 4 · accession 0001390478-16-000082
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Thomas Burns
Officer — Principal Accounting Officer
Period of report
Feb 23, 2016
Accepted (ET)
Mar 4, 2016 · 3:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $0.84 | Feb 23, 2016 | A | 75,000 | A | — | Feb 23, 2026 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Granted pursuant to the Issuer's Amended & Restated 2007 Incentive Plan.
- F2The stock option will vest in 16 equal, quarterly installments over 4 years beginning 3 months from the date of grant, as long as the Reporting Person remains in the Issuer's continuous employ through the vesting period.